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Abstract
Introduction Measuring bone mineral density (BMD) is a
widely accepted strategy for identifying subjects with an
increased risk of fracture. However, because of limited
availability of BMD technology in some communities and
cost considerations, it has been proposed that BMD
measurements be targeted to subjects with risk factors for
osteoporosis. Recently, many risk assessment indices have
been developed to identify women who are more likely to
have low BMD and thus undergo BMD testing. The
objective of this study was to compare the performance of
four risk indices for osteoporosis in white women in
Morocco.
Methods We analysed in an epidemiological cross-sectional
study the records for 986 postmenopausal white Moroccan
women seen at an out-patient rheumatology centre. Four
osteoporosis risk index scores were compared to bone
density T-scores. The ability of each risk index to identify
women with low BMD (T-score<−2.0) or osteoporosis
(T<−2.5) was evaluated.
Results Using an Osteoporosis Self-Assessment Tool
(OST) score<2 to recommend DXA referral, we found that
sensitivity ranged from 61% at the lumbar spine to 85% at
the total hip to detect BMD T-scores of −2.5, and
specificity ranged from 62% at the lumbar spine to 67%
at the total hip. The negative predictive value was high at
all skeletal sites (79–98%), demonstrating the usefulness of
the OST to identify patients who have normal BMD and
should not receive DXA testing. All risk indices performed
similarly and showed better results in identifying women
with osteoporosis or low BMD based on hip measurement.
Conclusions This is the first study that validated several
risk osteoporosis indexes in Moroccan women. The
performance of these risk indices among women in
Morocco was similar to that reported earlier for other
samples in Asian countries, the US, and Belgium. The OST
and other risk indices are effective and efficient tools to
help target high-risk women for DXA measurement.
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Introduction
Osteoporosis is a systemic skeletal disorder characterized by
low bone mass and micro-architectural deterioration of bone
tissue, and as a consequence an increase in bone fragility and
susceptibility to fracture [1]. It has enormous health and
socioeconomic implications in terms of morbidity, mortality
and disability worldwide [2]. In Morocco (30 million
inhabitants), the age-adjusted 1-year cumulative incidence
of hip fracture has been estimated to 52.1/100,000 [95%
confidence interval (CI) 40.9–63.3] in women in 2002 [3].
Bone mineral density (BMD) is widely recognized as the
strongest predictor for future fracture occurrence, similar to
an increased blood pressure level for the risk of stroke.
Screening for low BMD by using dual energy x-ray
absorptiometry (DXA), the gold standard diagnostic tool
for osteoporosis, is a widely accepted strategy for identify-
ing subjects with an increased risk of fracture. However,
mass screening with use of DXA scanning is not recom-
mended without some selection of the target population.
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Furthermore, because of limited availability of BMD
technology in some communities and cost considerations,
it has been proposed that BMD measurements be targeted
to subjects with risk factors for osteoporosis. Recently,
many epidemiological studies have identified clinical risk
factors for osteoporosis to develop risk assessment indices.
The purpose of the risk assessment indices is not to
diagnose osteoporosis or low BMD, but to identify women
who are more likely to have low BMD. These patients can
then be referred for BMD measurements. Such indices,
while not identifying all cases of osteoporosis, increase the
efficiency of BMD measurement by focusing on subjects
who are at increased risk [4–7].
The easiest to use in clinical practice is certainly the
Osteoporosis Self-assessment Tool (OST), which is
based simply on age and weight [8]. It was developed
and validated in several studies in Asian and white
populations [9–13]. Other risk tools are also based on age
and weight, in combination with up to four additional risk
factors; these include the Osteoporosis Risk Assessment
Instrument (ORAI) [14], the Simple Calculated Osteopo-
rosis Risk Estimation (SCORE) [15], and the Osteoporosis
Index of Risk (OSIRIS) [16]. These four risk assessment
tools have been proposed for increasing awareness of
osteoporosis and for encouraging more efficient use of
BMD measurements in patients who are likely to have low
bone mass, especially in asymptomatic postmenopausal
women.
Our aims were to assess the validity of these risk indices
in a population of 986 white women from Morocco, and to
compare the performance of the four tools (OST, ORAI,
SCORE and OSIRIS) in identifying women at risk of low




We analysed a database that included medical data on patients
either consulted spontaneously or referred for a BMD
measurement between April 2004 and July 2005 to our
department located at the Rheumatology and Physical
Rehabilitation Centre, Military Hospital Mohammed V
(University of Rabat) in Morocco. Postmenopausal women
>45 years at the date of consultation were included in our
sample. Referral was based on diagnostic judgment of the
referring physician. Informed consent was obtained from all
eligible study participants. Patients with Paget’s disease and
advanced osteoarthritis were excluded. All participants
underwent a structured questionnaire which concentrated on
those variables for which published evidence suggested an
association with osteoporosis or low BMD: current treatment
for health complaints (including the presence of low back
pain), fractures, presence of a disease, use of birth control
pills, use of other hormones, ovariectomy, age of menopause,
years between menarche and menopause (fertile years),
number of pregnancies, family history of osteoporosis, use
of toxic substances (alcohol and tobacco), calcium intake, and
occupational exercise and sports in the present and past.
Densitometry measurements
All BMD measurements were performed on a Lunar Prodigy
Vision machine (General Electric Inc). The DXA scans were
obtained by standard procedures supplied by the manufacturer
for scanning and analysis. The BMD measurements were
carried out by two experienced technicians. Daily quality
control was carried out by measurement of a Lunar phantom.
At the time of the study, phantom measurements showed
stable results. The phantom precision expressed as the CV (%)
was 0.08. Moreover, reproducibility has been assessed
recently in clinical practice and showed a smallest detectable
difference of 0.04 g/cm2 (spine) and 0.02 (hips) [17]. Patient
BMD was measured at the lumbar spine (L1-4) (anteropos-
terior projection) and the femurs (dual femur). The mean
result of the measure of the two femurs (total hip) was used.
BMD values, expressed in g/cm2, were converted into T
scores, expressed in standard deviations (SDs), using French
reference values. We used the WHO classification range to
categorize subjects as normal (T >−1), osteopenic (−2.5<
T≤−1), or osteoporotic (T≤−2.5). A subcategory was defined
as "low BMD", for all subjects with T ≤−2.0, to allow
comparison to published results for some risk indices that
were based on this cut-off. Further, this cut-off is widely used
in many communities to detect pre-osteoporotic patients.
Variables and risk scores
The OST, ORAI, SCORE, and OSIRIS indices were
derived according to the algorithms suggested by their
developers (Table 1). The following dichotomous cut-offs
for DXA referral were used: <2 for OST, >7 for SCORE,
>8 for ORAI and <1 for OSIRIS. Also, three risk categories
were used for each index, according to their developer’s
recommendations and the validation of some indices in
American and European populations.
Statistical analysis
Prevalence of osteoporosis in each of these three categories
was determined using the WHO criteria. Receiver operating
characteristic (ROC) analyses were performed to evaluate
the discriminatory performances of OST, ORAI, SCORE,
and OSIRIS, and the area under the curve (AUC) was
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computed for each. To assess the internal validity of the
indices, sensitivity was defined as the proportion of the
population with low BMD correctly classified by the risk
index (true positive fraction) and specificity was defined as
the proportion with normal BMD correctly identified by the
risk index (true negative fraction). ROC curves provided a
graphical representation of the overall accuracy of a test by
plotting sensitivity against (1-specificity) for all thresholds,
while the AUC quantified the accuracy of the test. We also
calculated the positive predictive value (PPV) and negative
predictive value (NPV) to evaluate the external validity of
each tool. The PPV and NPV represent the proportion of
women who tested positive or negative (as classified by the
four tools) and who truly had, or did not have, BMD below
the T-score threshold being tested, respectively.
We evaluated OST, ORAI, SCORE, and OSIRIS at
the BMD T-score thresholds of −2.5 and −2.0, to assess
the performance of those indices in predicting osteopo-
rosis and low bone mass, respectively. The ability of the
tools to detect different thresholds of low BMD was also
evaluated for various anatomical sites (total hip, femoral
neck, L1–L4) of densitometric measurement. Statistical
analysis used SPSS statistical software (SPSS Inc,
Chicago, Ill).
Results
The mean age of the women in our sample was 59.8 (±8.8)
years, ranging from 46 to 92 years. Table 2 shows their
basic demographic data. 15% reported a non-traumatic
fracture after age 45 at the wrist, rib, or hip. The prevalence
of osteoporosis at all sites increased progressively with age.
Of the women in our study, 33% were osteoporotic
(T<−2.5) at one or more skeletal site, 45% had a low
BMD (T<−2.0), and 77% were classified as osteopenic
according to the WHO operational definition. Table 3
shows the performance of the four risk indices in
Table 2 Characteristics of the participants (n=986)
Mean SD Minimum Maximum
Age (years) 59.8 8.1 46 92
Weight (kg) 71.8 12.9 35 118
Body mass index
(kg/m2)
35.6 6.3 17.7 56.6
Spine BMD (g/cm2) 0.962 0.168 0.526 1.617
Spine T score −1.67 1.4 −5.30 3.80
Femoral neck BMD
(g/cm2)
0.887 0.14 0.360 1.145
Femoral neck T score −1.16 1.08 −4.30 3.20
Total hip BMD (g/cm2) 0.837 0.139 0.700 1.359
Total hip T score −0.92 1.160 −4.30 3.80
Table 1 Method of calculation of the evaluated indices
Factor Score
OST (Osteoporosis Self-assessment Tool)
Body weight (kg) 0.2×(body weight-age)
Age (years)
SCORE (Simple Calculated Osteoporosis Risk Estimation)
Race other than Black +5
Rheumatoid arthritis +4
Non-traumatic fracture after age
45 years
+4 per fracture, up to a
maximum of 12
Age +3 for each decade
Oestrogen therapy +1 if never
Weight −1 for each 10 lb (4.5 kg)
ORAI (Osteoporosis Risk Assessment Instrument)
Age >75 years +15
Age 65–74 years +9
Age 55–64 years +5
Body weight <60 kg +9
Body weight 60–70 kg +3
Oestrogen therapy +2 if not currently using
oestrogen
OSIRIS (Osteoporosis Index of Risk)
Body weight (kg) +0.2×body weight
Age (years) −0.2×age
History of low impact fracture(s) −2
Oestrogen therapy +2
Table 3 Prevalence of low BMD and osteoporosis by BMD
measurement site and risk category
Risk category Total T score<2.5
Hip FN L1–L4 Any
8.3% 11.6% 31.1% 33.7%
OST
>1 (low risk) 69.6% 2.3% 4.2% 23.0% 24.1%
−3 to 1
(moderate risk)
27.0% 17.3% 22.3% 46.6% 51.9%
<−3 (high risk) 3.4% 58.3% 73.5% 73.5% 85.3%
SCORE
<7 (low risk) 34.7% 1.5% 2.3% 11.4% 11.7%
7–15
(moderate risk)
59.4% 8.4% 11.9% 39.2% 42.2%
>15 (high risk) 5.9% 48.3% 62.1% 65.5% 77.6%
ORAI
<9 (low risk) 63.8% 1.7% 3.3% 21.9% 22.9%
9–17
(moderate risk)
29.5% 13.4% 19.2% 44.7% 47.4%
>17 (high risk) 6.7% 48.5% 56.1% 59.1% 75.8%
OSIRIS
>1 (low risk) 68.9% 2.4% 4.1% 22.8% 23.9%
−3 to 1
(moderate risk)
26.5% 14.6% 19.5% 44.8% 49.4%
<−3 (high risk) 4.7% 60.9% 76.1% 76.1% 89.1%
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identifying patients at various BMD measurement sites and
thresholds (T score values of −2 and −2.5). Increasing
prevalence of osteoporosis (T<−2.5) with ascending risk
category (low, medium, high) was apparent for all four risk
tools. For example, the prevalence of osteoporosis based on
total hip BMD was approximately 2%, 17%, and 58% at
the low (70% of women), medium (27% of women), and
high (3% of women) OST risk levels. Of the women in our
study classified as high risk, 91% had low bone mass and
85% had osteoporosis at any site. At the considered
thresholds, OST, SCORE, ORAI, and OSIRIS identified
respectively, 75%, 88%, 77%, and 76% of the patients with
normal BMD who subsequently should not have been
recommended for densitometry, since according to their
score they were ‘low risk’.
Using the dichotomous cut-off value of <2, the sensitiv-
ity of OST in identifying individuals at increased risk of
osteoporosis ranged from 82% for lumbar spine to 91% at
the total hip region. The corresponding specificity of OST
ranged from 24% at the total hip to 34% at any given site
(Table 4). SCORE had a higher sensitivity than OST but
lower specificity and NPV. At the OST cut-off point of 2,
and using a BMD T-score threshold of −2.5 for any site,
51% of the subjects were misclassified (most of these were
false positives); the proportion of misclassified patients for
single BMD sites was 45% at the total hip, 32% at the
femoral neck, and 49% at the lumbar spine site. The AUC
was consistently high (around 0.8) for the two hip sites, and
somewhat lower for the spine (Table 5), indicating good
test performance. For each combination of BMD measure-
ment and T-score cut-off, the AUC results were similar for
all four risk tools.
Discussion
The National Institutes of Health consensus conference
defined osteoporosis as a disease of increased skeletal
fragility accompanied by low BMD (T score below −2.5)
and micro-architectural deterioration [18]. The preferred
sites for diagnostic purposes are BMD measurements made
at the hip, either at the total hip or the femoral neck [19].
The availability of new effective treatments for osteoporosis
emphasised to recommend BMD measurements for patients
considered at high risk. Several guidelines have been
developed to select which patients should undergo DXA
testing [20–23].
In our study involving white women aged 45 years
and more, the OST successfully identified most women
with hip osteoporosis and low BMD with a sensitivity of
85%, specificity of 62% and NPV of 98% at the total hip
site. The OST, based only on age and weight, performed
as well as the more complex risk assessment indices
(SCORE, ORAI, and OSIRIS) in identifying women at
low risk of osteoporosis who would not need DXA
testing (98% of patients classified as low risk with OST
do not have osteoporosis at the total hip). In a
population-based sample of postmenopausal Japanese
women [10], the OST had a sensitivity of 90% and
Table 4 Performance of the risk indices by BMD measurement site and T-score cut-off (%)
Tool Total hip Femoral Neck L1–L4 spine Any site
Se Sp PPV NPV Se Sp PPV NPV Se Sp PPV NPV Se Sp PPV NPV
T score<2.5
OST 85 62 17 98 85 64 24 97 61 67 46 79 62 69 51 78
SCORE 93 62 12 88 93 38 16 97 87 44 41 88 88 46 45 46
ORAI 86 68 20 98 81 69 26 69 55 72 47 72 56 74 52 77
OSIRIS 80 73 21 97 75 74 28 95 49 77 49 77 51 79 55 76
T score<2
OST 76 67 35 92 70 67 38 88 55 65 61 70 57 66 63 71
SCORE 94 40 12 94 90 42 31 93 82 49 57 77 83 77 58 50
ORAI 70 72 37 91 67 72 41 88 50 75 63 64 52 65 66 77
OSIRIS 66 77 41 90 61 77 44 87 43 79 63 62 45 63 66 80
NPV: negative predictive value, PPV: positive predictive value, Se: sensitivity, Sp; specificity
Table 5 Areas under the ROC curves for the four evaluated
assessment tools by BMD measurement site and T-score cut-off
Tool Total hip Femoral neck L1–L4 spine Any site
T score<2.5
OST 0.853 0.823 0.720 0.742
SCORE 0.851 0.820 0.681 0.723
ORAI 0.829 0.810 0.680 0.699
OSIRIS 0.850 0.820 0.721 0.735
T score<2
OST 0.775 0.768 0.723 0.730
SCORE 0.768 0.759 0.679 0.695
ORAI 0.759 0.790 0.690 0.703
OSIRIS 0.780 0.780 0.716 0.745
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specificity of 45%. This tool was similarly validated in
Korean [9], Filipino [12] and Belgian women [11]. Table 6
shows the prevalence of postmenopausal women with hip
osteoporosis by OST risk level in the current study and
other published studies.
Avoiding unnecessary testing among low risk patients
can substantially reduce cost for the community and the
patient (social health insurance only covers 15% of
Moroccan population). For example, in this sample of
Moroccan women, 69% of the women were classified as
low risk using OST, and thus would not need to be referred
to DXA testing. Of these, only 2.3% actually had
osteoporosis based upon total hip BMD. At the same time,
using OST to select the 31% of women at risk for BMD
measurements, 80% of all women with osteoporosis at the
hip level would be identified.
A risk assessment tool such as OST does not need to
have both high sensitivity and high specificity. Indeed,
there is no risk of harm to the patient from unnecessary
treatment or invasive diagnostic testing in case of a false-
positive result from OST. Although some women who do
not have low BMD were classified as increased risk (false
positives) and would be referred for testing, some of these
women would have undergone testing anyway if OST were
not used. Furthermore, treatment for low BMD would only
be initiated upon confirmation by DXA: a safe and non-
invasive diagnostic procedure.
Despite differences in ethnicity of the studied popula-
tions and the reference databases used to calculate T scores,
we found the performance of OST in this sample similar to
that reported among Asian, American and European women
especially at the hip level. As it was the case in Richy et al.
study [11], the results were slightly less concordant at the
lumbar spine. We used the same risk tool categories as
Geusens et al. [13] to compare the performance of the
various tools in a different population, and found very
similar results for OST at the T-score ≤−2.0 and ≤−2.5 cut-
offs. The SCORE, ORAI, OSIRIS, and OST are validated
risk indices that can help physicians and public health
authorities to focus DXA testing on individuals at increased
risk of osteoporosis. All four risk tools performed similarly,
and identified a significant proportion of all women at low
risk who would not benefit from BMD measurements.
These indices have been studied and validated in several
different large populations.
As with most studies, our study has limitations. For
example, the subjects in our sample were either referred or
came in spontaneously for osteoporosis evaluations, and
may differ in some ways from the general population.
Another limit is the use of French BMD reference range for
calculating T-scores. However, it was felt that awaiting the
Moroccan reference database, now under study in our
centre [24], the French population has more similarities
with the Moroccan population than the US population used
in NHANES III. Moreover, hip incidence measured in
Morocco showed similar results to the south of France [3].
Another limitation of this kind of studies is that it does not
take into account the risk of fracture, which is the main
purpose of treating osteoporosis. DXA itself has a low
sensitivity and about half of patients who fracture do not
have densitometric osteoporosis. However, the main objec-
tive of our study and similar studies is to identify patients
with low BMD in order to avoid unnecessary exams, which
is very important in developing countries, while developing
a fracture risk assessment tool needs prospective longitudinal
cohorts.
In summary, measuring BMD is the best method of
identifying patients with osteoporosis to consider for
treatment. However, measuring BMD in all postmenopaus-
al women is not feasible especially in developing countries
such as Morocco. The OST tool can help target BMD
measurements to women at risk. Its high sensitivity,
acceptable specificity and very high negative predictive
value allows for the safe exclusion of healthy women, in
order to reduce unnecessary bone density examinations in
those who are at lowest risk. ORAI, SCORE, and OSIRIS
provided similar performance in this setting. The main
advantage in using the OST index is that it is the simplest
and quickest to calculate, and thus to use in general practice
as a first-line prescreening tool in post-menopausal women.
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